Kenvue stock (US49177J1025): Dividend payment and Kimberly-Clark takeover review keep NYSE name in focus

Kenvue stock on the New York Stock Exchange stays in focus for U.S. investors as the consumer health company proceeds with a quarterly cash dividend and navigates regulatory review of a proposed USD 49 billion acquisition by Kimberly-Clark. According to a Zacks dividend update dated 04/29/2026, Kenvue set a quarterly dividend of USD 0.20 per share for shareholders of record on 05/13/2026, payable on 05/27/2026, equivalent to an annualized payout of USD 0.82 per share and a yield of roughly 3.8% based on recent trading levels. The stock trades in the United States under the ticker KVUE on the NYSE, anchoring the name firmly in the U.S. consumer equities universe.

On the corporate front, Kimberly-Clark announced on 05/29/2026 that its proposed acquisition of Kenvue for USD 49 billion is under review by China's State Administration for Market Regulation, highlighting that regulatory approvals remain outstanding and the transaction is not yet closed. Kimberly-Clark has indicated that the combined consumer health and personal care business could generate around USD 32 billion in annual revenue once the deal is completed, with closing currently anticipated in the second half of 2026 subject to global antitrust clearances. This prospective tie-up keeps Kenvue prominent in U.S. dealmaking discussions while the shares continue to change hands on the NYSE.

The stock most recently traded in the low-USD 20s, with data from DRIPCalc showing Kenvue at around USD 21.61 per share, implying a market capitalization near the mid-USD 30 billion range as of late May 2026. CompaniesMarketCap, which tracks listed equities globally, cites a market value of approximately USD 33.9 billion for Kenvue in May 2026 and around USD 34.0 billion on 05/27/2026, demonstrating that the stock continues to be actively priced by the market pending clarity on the takeover timetable. In Germany, the U.S.-listed shares are also traded on off-exchange platforms such as Tradegate, allowing euro-based investors to participate indirectly in the NYSE quotation.

Operationally, the company delivered Q1 2026 results on 05/07/2026, reporting earnings per share of USD 0.32 compared with a consensus estimate of USD 0.27, and revenue that grew 4.5% year-on-year according to MarketBeat data, underlining ongoing top-line progress in the consumer health portfolio even as the strategic review continues. A prior analysis of Q4 2025 results from Kavout highlighted mixed dynamics, with Kenvue posting roughly USD 3.8 billion in revenue, above expectations, while diluted EPS came in at USD 0.17 and adjusted EPS reached USD 0.27, suggesting that margin and cost trends remain an area of focus heading into 2026. Dividend metrics from Zacks show that with an annual payout of around USD 0.82 per share and a payout ratio near 69% of earnings, the company balances shareholder returns with investment in its brands.

As of: 05/30/2026

By the editorial team - specialized in equity coverage.

Kenvue: core business model

Kenvue positions itself as a focused consumer health player built around self care, skin health and beauty, and essential health brands that aim to drive repeat purchases across pharmacies, mass retailers, and e-commerce channels worldwide.

Insider activity and ownership structure

Public information sources show no major insider buying or selling headlines tied specifically to late May 2026, but ownership and capital return data provide some insight into how Kenvue is structured as it approaches a potential change of control. The quarterly dividend of USD 0.20 per share announced on 04/29/2026 and paid on 05/27/2026 underscores a shareholder remuneration framework that management has kept in place after the company’s 2023 spin-off and initial public offering. With a payout ratio cited at roughly 69% of earnings, the group returns a substantial portion of profits to its investor base while maintaining room for reinvestment in brands and potential deleveraging ahead of any transaction close.

Market capitalization data from CompaniesMarketCap around USD 33.9 billion in May 2026 suggests a wide base of institutional and retail shareholders, as is typical for a large-cap U.S. consumer name listed on the NYSE. While the planned USD 49 billion cash-and-stock transaction with Kimberly-Clark would eventually reshape the share register by rolling Kenvue into a larger global personal care entity, regulatory filings and deal commentary as of 05/29/2026 indicate that the agreement remains pending and Kenvue continues to operate as a standalone company with its existing public ownership structure.

Conclusion

Kenvue’s combination of a roughly 3.8% dividend yield, quarterly cash distribution of USD 0.20 per share, and steady Q1 2026 revenue growth of about 4.5% keeps the NYSE-listed consumer health stock on the radar of income and defensive-growth investors. At the same time, the proposed USD 49 billion acquisition by Kimberly-Clark, now undergoing regulatory review by SAMR in China with expected closing in the second half of 2026, adds an M&A angle that could influence how the market prices Kenvue’s standalone fundamentals and corporate trajectory in the months ahead. Until the deal either closes or is revised, the share price is likely to be driven by a mix of ongoing operating performance, dividend stability, and shifting probabilities around regulatory approvals.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.